SynthesisAndrology2026
A Systematic Review on Administration of Botulinum Toxin in the Management of Male Sexual Dysfunctions.
Synthesis in Andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research trends in the comorbidity of erectile dysfunction and premature ejaculation: a 20-year bibliometric analysis [2005-2025].Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMale sexual dysfunctions (SDs) like erectile dysfunction (ED), premature ejaculation (PE), and Peyronie's disease (PD) are highly prevalent conditions affecting the quality of life of men and their partners. Botulinum toxin (BTX) is emerging as a promising injectable therapy to treat male SDs.
objectiveTo systematically review the current evidence on the use of BTX in the treatment of male SDs. MATERIALS AND
methodsPubMed, Cochrane, and EMBASE databases were queried for all published studies indexed up to October 2024 using predefined keywords.
resultsOf 108 identified articles, 9 (6 on ED, 2 on PE, and only 1 on PD) met our inclusion criteria. In ED, BTX improved International Index of Erectile Function-Erectile Function domain (IIEF-EF) scores in 41%-57.4% of patients, with benefits lasting up to 6 months. In PE, BTX increased ejaculation latency and subjective satisfaction at 1-3 months, but the effects diminished by 6 months. In PD, a single study showed a significant reduction in penile curvature (-7.9°), plaque thickness, and penile pain. Adverse effects were mild and local, reported in less than 10% of cases.
conclusionsBTX injections demonstrate promising improvements in erectile function, ejaculation latency, and penile curvature with a favourable safety profile. However, current evidence is limited by small, heterogeneous studies and the absence of large randomized controlled trials. Further research is needed to establish optimal dosing, timing, and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.